Pre-Market Surge For Precision BioSciences (DTIL) On Groundbreaking Trial Data
After a landmark clinical trial revealed a full clinical response in the first infant dosage, Precision BioSciences, Inc. (NASDAQ: DTIL) shares are rocketing this morning. DTIL stock jumped 36.70% to $6.15 as of the most recent pre-market check, indicating that investors are becoming more confident in the company’s cutting-edge gene-editing capabilities. Breakthrough in Neonatal Gene […]
Pre-Market Surge For Precision BioSciences (DTIL) On Groundbreaking Trial Data Read More »